Pharmacia Expects Camptosar Sales To Rebound As Safety Concerns Resolve
Executive Summary
Pharmacia expects sales of its colorectal cancer therapy Camptosar to rebound following a positive review of postmarketing safety data by FDA's Oncologic Drugs Advisory Committee